Hematopoiesis News Volume 7.23 | Jun 14 2016

TOP STORY

New Approach Could Make Bone Marrow Transplants Safer

Researchers developed a non-toxic transplantation procedure using antibodies to specifically target blood stem cells in mice, an approach they hope will make blood stem cell transplants for these patients far less toxic. [Press release from Harvard Stem Cell Institute discussing online prepublication in Nature Biotechnology] Press Release | Abstract

(Ranked by impact factor of the journal)

Dual Targeting of p53 and c-MYC Selectively Eliminates Leukemic Stem Cells

The authors showed, using proteomics, transcriptomics and network analyses, that in human leukemic stem cells, aberrantly expressed proteins, in both imatinib-responder and non-responder patients, are modulated in concert with p53 (also known as TP53) and c-MYC regulation. [Nature] Abstract | Press Release

DNMT3A Loss Drives Enhancer Hypomethylation in FLT3-ITD-Associated Leukemias

Investigators showed that DNMT3A loss synergizes with the FLT3 internal tandem duplication in a dose-influenced fashion to generate rapid lethal lymphoid or myeloid leukemias similar to their human counterparts. [Cancer Cell] Abstract | Graphical Abstract | Press Article

ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis

In blast crisis chronic myeloid leukemia, researchers showed that increased JAK2 signaling and BCR-ABL1 amplification activate adenosine deaminase acting on RNA1 (ADAR1). [Cell Stem Cell] Abstract | Graphical Abstract

Functional Interdependence of BRD4 and DOT1L in MLL Leukemia

Genetic disruption or small-molecule inhibition of bromodomain-containing protein 4 (BRD4) and disruptor of telomeric silencing 1-like (DOT1L) showed marked synergistic activity against MLL leukemia cell lines, primary human leukemia cells and mouse leukemia models. [Nat Struct Mol Biol] Abstract

S6K1 Regulates Hematopoietic Stem Cell Self-Renewal and Leukemia Maintenance

Scientists demonstrated that S6 kinase 1 (S6K1) deficiency impairs self-renewal of murine hematopoietic stem cell by reducing p21 expression. [J Clin Invest] Full Article

Smad4 in Osteoblasts Exerts a Differential Impact on HSC Fate Depending on Osteoblast Maturation Stage

Researchers investigated how Smad4 modulates hematopoietic stem cells (HSCs) fate at distinct stages of osteoblasts development. [Leukemia] Abstract

Embryonic Hematopoiesis in Vertebrate Somites Gives Rise to Definitive Hematopoietic Stem Cells

By transgenic lineage tracing, investigators found that a subset of cells within the forming somites emigrate ventromedially and mix with lateral plate mesoderm-derived primitive hematopoietic cells before the blood circulation starts. [J Mol Cell Biol] Abstract | Full Article

CLINICAL RESEARCH

Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group

Chemotherapy was substantially reduced safely in one-quarter of children with acute lymphoblastic leukemia (ALL) who were selected on the basis of undetectable minimal residual disease levels, without jeopardizing the survival rate. [J Clin Oncol] Abstract

Pexmetinib: A Novel Dual Inhibitor of Tie-2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia

Researchers showed that elevation of angiopoietin-1 in myelodysplastic CD34⁺ stem-like cells is associated with higher risk disease and reduced overall survival in myelodysplastic syndromes and acute myeloid leukemia patients. [Cancer Res] Abstract

Hematopoietic Stem Cell Transplantation for Sickle Cell Disease – Current Practice and New Approaches

Challenges remain in improving the safety and efficacy of hematopoietic stem cell transplant from alternate donors. Early results from gene therapy may provide another curative option in patients with sickle cell disease. These approaches show early promise, but larger, longitudinal studies are needed to better determine the optimal clinical circumstances for transplant in sickle cell disease. [Br J Haematol] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Galena Biopharma Presents GALE-401 Combined Safety Data at the European Hematology Association 21st Congress

Galena Biopharma, Inc. announced that combined safety data from the Company’s GALE-401 clinical trials were presented. [Press release from Galena Biopharma, Inc. discussing research presented at the European Hematology Association 21^st Congress, Copenhagen] Press Release

Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association

Seattle Genetics, Inc. highlighted data evaluating vadastuximab talirine in combination with hypomethylating agents in frontline patients with acute myeloid leukemia who had declined intensive therapy. [Press release from Seattle Genetics discussing research presented at the European Hematology Association 21^st Congress, Copenhagen] Press Release

Celator Pharmaceuticals^® Announces Positive Results in Patients with FLT3 Mutation from the Phase III Trial in High-Risk Acute Myeloid Leukemia

Celator Pharmaceuticals, Inc. announced positive response rate results in acute myeloid leukemia patients with FLT3 (FMS-like tyrosine kinase-3) mutation were presented. [Press release from Celator Pharmaceuticals, Inc. discussing research presented at the European Hematology Association 21^st Congress, Copenhagen] Press Release

BloodCenter of Wisconsin and San Diego Blood Bank Announce Collaborative Offering Called Celluvative

BloodCenter of Wisconsin and the San Diego Blood Bank have created a strategic partnership to accelerate advancements in research and patient care. [Celluvative] Press Release

GlycoMimetics’ GMI-1271 Receives FDA Fast Track Designation for Treatment of Acute Myeloid Leukemia

GlycoMimetics, Inc. announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its novel E-selectin antagonist GMI-1271 for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) and elderly patients aged 60 years or older with AML. [GlycoMimetics, Inc.] Press Release

NEW 34^th International Congress of the International Society of Blood Transfusion (ISBT)
September 3-8, 2016
Dubai, United Arab Emirates

Visit our events page to see a complete list of events in the hematopoiesis community.

NEW Postdoctoral Fellow – Tumor Microenvironment and Cancer Stem Cells (Duke University)

Technical Sales Representative (STEMCELL Technologies Inc.)

Scientist – Hematology (STEMCELL Technologies Inc.)

Postdoctoral Researcher – Hematology and Oncology (Hannover Medical School)

Cytogenetics Laboratory Supervisor (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Hematopoietic Stem Cell Biology (Novartis)

Research Assistants and Associates – Leukemia and Stem Cell Biology (King’s College London)

Postdoctoral Research Associate – Myeloid Leukemia (Upstate Medical University)

Postdoctoral Fellow – Leukemia Lymphoma (Emory University)

Postdoctoral Scientist – Mouse Hematopoiesis (Lund University)

Postdoctoral Fellow – Hematopoietic Stem Cell Biology and Blood Disorders (Brigham & Women’s Hospital)

Research Technician – Hematopoietic Stem Cell Biology (Fred Hutchinson Cancer Research Center)

Postdoctoral Research Associate – Stem Cell Aging Biology (University of Southern California)

Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here.